Low Back PainSpondylolisthesisSpondylosis LumbarBalance Assessment
Investigational drug(s) / intervention(s)
Assessment of balance will be measured by The Biodex Balance System (BBS) which computes Postural Stability key indices: the medial-lateral stability index (MLSI), anterior-posterior stability index
Assessment of balance will be measured by The Biodex Balance System (BBS) which computes Postural Stability key indices: the medial-lateral stability index (MLSI), anterior-posterior stability index: Low back pain (LBP) is a leading cause of disability worldwide and is often associated with postural and balance impairments. However, limited evidence exists on how these deficits differ among specific types of LBP such as lumbar spondylosis, spondylolisthesis, and disc prolapse. Understanding these variations is crucial for accurate assessment and targeted rehabilitation. Evaluating balance using the Biodex Balance System can help identify the extent of impairment and guide physiotherapists in developing individualized rehabilitation programs that enhance postural control, stability, and functional performance, ultimately improving quality of life and reducing fall risk among LBP patients.
Study summary
this study aims to evaluate balance using the biodex balance system among patients with spondylosis, spondylolisthesis, and lumber disc prolapse.
Eligibility
Sex
ALL
Min age
35 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Diagnosis of chronic low back pain (≥3 months duration) (Ge et al., 2021). Referred from orthopedic surgeons with confirmed diagnosis of lumbar spondylosis, spondylolisthesis or lumber disc prolapse affecting L4-L5 or L5 S1( Hlaing et al., 2020) depending on imaging findings (MRI, CT or X-ray scan within the last 6 months):
* Lumbar spondylosis; defined as degenerative disc disease, osteophyte formation with or without facet joint arthropathy (Natarajan et al., 2021; Christe et al., 2020).
* Lumbar spondylolisthesis; defined as anterolisthesis of one vertebral body over another, graded via the Meyerding scale (grade 1 or 2) (Giordan et al., 2023; Chuang et al., 2018).
* Lumbar disc prolapse; defined as protrusion, herniation of intervertebral disc (Kang et al., 2016; Hahne et al., 2019).
* Age of patients ranges from 35 to 55 years (Albeshri, et.al., 2017)
* Both genders will be included in the study
* Pain intensity: ≥ 4/10 on a numerical pain rating scale (Thong et al., 2011).
* BMI ranged from (18.5-29.9 kg/m²) (Karimi et al., 2008; Soliman et al., 2017).
* Healthy subjects are healthy volunteers and without any Musculoskeletal disorders (Karimi et al., 2008).
Exclusion Criteria:
* The following patients will be excluded from the study patients with:
* Prior lumbar spine surgery or neurological disorders (e.g., parkinson's, stroke) that may influence balance (soliman et al., 2017).
* Fractures of the spine, pelvis or lower extremities, (Karimi et al., 2008).
* Leg length discrepancy(Karimi et al., 2008).
* Systemic disease such as arthritis, tuberculosis, liver or kidney failure. (Karimi et al., 2008).
* Patients with chronic non-specific low back pain.
* Patients exhibiting red flag symptoms such as urinary or fecal incontinence, saddle anesthesia, progressive motor deficits (e.g., foot drop), or other signs of serious neurological compromis (Ruhe et al., 2011).
* Participants experiencing low back pain with pain radiating distaly below the level of knee (Hlaing et al., 2020).
Primary outcome measure(s)
Postural stability ( Overall Stability Index) — All postural assessments will be performed for 20 seconds Postural stability will be assessed using the Biodex Balance System through the Overall Stability Index (OSI).The OSI reflects the degree of platform sway, with lower values indicating better balance control. Measurements will be taken under six standardized conditions to evaluate both static and dynamic balance performance. These conditions include:
Double-Leg, Eyes Open (DLEO)
Double-Leg, Eyes Closed (DLEC)
Single-Leg, Eyes Open (SLEO) - Dominant Leg
Single-Leg, Eyes Closed (SLEC) - Dominant Leg
Single-Leg, Eyes Open (SLEO) - Non-Dominant Leg
Single-Leg, Eyes Closed (SLEC) - Non-Dominant Leg
Postural Stability: Medial-Lateral Stability Index (MLSI) — All postural assessments will be performed for 20 seconds The Medial-Lateral Stability Index (MLSI) will be obtained from the Biodex Balance System to assess side-to-side postural control. Higher MLSI values indicate greater medial-lateral sway, while lower values reflect better stability in the frontal plane. the measurement will be in six conditions:
Double leg eyes open (DLEO), Double leg eyes closed (DLEC), Single leg eye open (SLEO) Dominant leg, Single leg eye closed (SLEC) Dominant leg, Single leg eye open (SLEO) Non-Dominant leg and Single leg eye closed (SLEC) Non-Dominant leg
postural stability: Anterior-Posterior Stability Index (APSI) — All postural assessments will be performed for 20 seconds The Anterior-Posterior Stability Index (APSI) will be measured using the Biodex Balance System to evaluate forward-backward postural control. Lower APSI values indicate improved stability in the sagittal plane, whereas higher values reflect increased anterior-posterior sway.
the measurement will be in six conditions: Double leg eyes open (DLEO), Double leg eyes closed (DLEC), Single leg eye open (SLEO) Dominant leg, Single leg eye closed (SLEC) Dominant leg, Single leg eye open (SLEO) Non-Dominant leg and Single leg eye closed (SLEC) Non-Dominant leg
Limits of Stability — All postural assessments will be performed for 20 seconds Limits of Stability will be assessed using the Biodex Balance System to evaluate the participant's ability to intentionally shift their center of gravity toward predefined targets without losing balance. The test measures directional control, reaction time, movement speed, and endpoint accuracy, with higher scores reflecting better dynamic balance and voluntary postural control. the measurement condition will be in Double leg eyes open (DLEO)
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.